Donald Landry - Sensient Technologies Independent Director
| SXT Stock | USD 74.11 0.23 0.31% |
Director
Dr. Donald W. Landry, M.D. Ph.D. is Independent Director of the Company. Dr. Landry is the Samuel Bard Professor and Chair of the Department of Medicine at Columbia Universitys College of Physicians and Surgeons. He also serves as its Director of the Division of Experimental Therapeutics and PhysicianinChief for the Medical Service at New York Presbyterian HospitalColumbia Medical Center. Dr. Landry was a member of the faculty of Columbia University since 1985. At Columbia, Dr. Landry developed the first artificial enzyme to degrade cocaine and his report in Science was voted one of top 25 papers in the world for 1993 by the American Chemical Society. His discovery that vasopressin can be used to treat vasodilatory shock fundamentally changed intensive care medicine. He also pioneered an embryosparing approach to the generation of human embryonic stem cells. Dr. Landry was a director of Tonix Pharmaceuticals Holding Corporationration since October 2011. Between June 2007 and October 2011, Dr. Landry served as a founding director of Tonix Pharmaceuticals, Inc., a whollyowned subsidiary of Tonix Pharmaceuticals Holding Corporationration Tonix Pharmaceuticals is a publicly traded company that develops nextgeneration medicines for common disorders of the central nervous system, including fibromyalgia, posttraumatic stress disorder, and episodic tensiontype headache. Dr. Landry was cofounder and was a member of LL Technologies LLC since 1996. LL Technologies LLC was formed to develop medications for central nervous system conditions. Dr. Landry was also a cofounder of Vela Pharmaceuticals, which developed several drugs for central nervous system disorders, including very low dose cyclobenzaprine for fibromyalgia syndrome. Cofounder of Vela Pharmaceuticals, a private company that developed several drugs for central nervous system disorders, including very low dose cyclobenzaprine for fibromyalgia syndrome. since 2015.
| Age | 66 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 777 East Wisconsin Avenue, Milwaukee, WI, United States, 53202-5304 |
| Phone | 414 271 6755 |
| Web | https://www.sensient.com |
Sensient Technologies Management Efficiency
The company has Return on Asset of 0.0612 % which means that on every $100 spent on assets, it made $0.0612 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1179 %, implying that it generated $0.1179 on every 100 dollars invested. Sensient Technologies' management efficiency ratios could be used to measure how well Sensient Technologies manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Sensient Technologies' Return On Capital Employed is comparatively stable compared to the past year. Return On Assets is likely to gain to 0.07 in 2025, whereas Return On Tangible Assets are likely to drop 0.06 in 2025. Change To Liabilities is likely to gain to about 31.4 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 224.9 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Donald Winter | Minerals Technologies | 72 | |
| Brendan Cummins | Ashland Global Holdings | 69 | |
| William CFA | Ashland Global Holdings | N/A | |
| Joseph Breunig | Minerals Technologies | 59 | |
| Jay Ihlenfeld | Ashland Global Holdings | 69 | |
| William Dempsey | Ashland Global Holdings | 69 | |
| Craig Rogerson | Ashland Global Holdings | 63 | |
| Marc Robinson | Minerals Technologies | 59 | |
| Robert Clark | Minerals Technologies | 57 | |
| EllenBlair Chube | Oil Dri | 39 | |
| Paul Hindsley | Oil Dri | 61 | |
| Daniel Florness | H B Fuller | 57 | |
| Paul Suckow | Oil Dri | 73 | |
| Carolyn Pittman | Minerals Technologies | 57 | |
| Robert Rock | Quaker Chemical | 70 | |
| John Roden | H B Fuller | 70 | |
| Ian Ashken | Element Solutions | 60 | |
| Maria Hilado | H B Fuller | 56 | |
| Steven Williams | Innospec | 69 | |
| Sanjay Hinduja | Quaker Chemical | 56 | |
| Jeffry Frisby | Quaker Chemical | 65 | |
Management Performance
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0612 |
Sensient Technologies Leadership Team
Elected by the shareholders, the Sensient Technologies' board of directors comprises two types of representatives: Sensient Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sensient. The board's role is to monitor Sensient Technologies' management team and ensure that shareholders' interests are well served. Sensient Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sensient Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elaine Wedral, Lead Independent Director | ||
| Craig Mitchell, President - Flavors and Fragrances Group | ||
| Carol Jackson, Independent Director | ||
| Sharad Jain, Independent Director | ||
| Adam Vanderleest, Controller VP | ||
| Michael Geraghty, President of Color Group | ||
| Deborah McKeithanGebhardt, Independent Director | ||
| Essie Whitelaw, Independent Director | ||
| Steve Morris, Flavors President | ||
| Edward Cichurski, Independent Director | ||
| John JD, General VP | ||
| Amy Agallar, Vice President Treasurer | ||
| Amy JD, VP Counsel | ||
| Amy Jones, Vice President Human Resources and Senior Counsel | ||
| Scott Morrison, Independent Director | ||
| Tobin Tornehl, Chief Accounting Officer, Vice President Controller | ||
| John Manning, Senior Vice President, General Counsel, Secretary | ||
| Mario Ferruzzi, Independent Director | ||
| Joseph Carleone, Lead Independent Director | ||
| Stephen Rolfs, Chief Financial Officer, Senior Vice President | ||
| E Mitchell, President - Flavors and Fragrances Group | ||
| Thierry Hoang, Vice President - Asia Pacific Group | ||
| Paul Manning, CEO and President Director, Member of Executive Committee, Member of Fin. Committee and Member of Scientific Advisory Committee | ||
| Donald Landry, Independent Director |
Sensient Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sensient Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0612 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.11 % | ||||
| Current Valuation | 3.75 B | ||||
| Shares Outstanding | 42.44 M | ||||
| Shares Owned By Insiders | 1.55 % | ||||
| Shares Owned By Institutions | 91.75 % | ||||
| Number Of Shares Shorted | 500.44 K | ||||
| Price To Earning | 26.09 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sensient Stock Analysis
When running Sensient Technologies' price analysis, check to measure Sensient Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sensient Technologies is operating at the current time. Most of Sensient Technologies' value examination focuses on studying past and present price action to predict the probability of Sensient Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sensient Technologies' price. Additionally, you may evaluate how the addition of Sensient Technologies to your portfolios can decrease your overall portfolio volatility.